Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay.
Identifieur interne : 004A40 ( PubMed/Curation ); précédent : 004A39; suivant : 004A41Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay.
Auteurs : M. Breidenbach [Allemagne] ; D. Rein ; T. Schmidt ; W. Heindel ; H. Kolhagen ; P. Mallmann ; C M KurbacherSource :
- Anti-cancer drugs [ 0959-4973 ] ; 2000.
Descripteurs français
- KwdFr :
- Adénosine triphosphate (métabolisme), Carcinome canalaire du sein (anatomopathologie), Carcinome canalaire du sein (radiothérapie), Femelle, Humains, Lymphangiosarcome (métabolisme), Lymphangiosarcome (traitement médicamenteux), Lymphangiosarcome (étiologie), Lymphoedème (traitement médicamenteux), Lymphoedème (étiologie), Mitoxantrone (administration et posologie), Paclitaxel (administration et posologie), Perfusions artérielles, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Sujet âgé, Syndrome, Tests de criblage d'agents antitumoraux, Tumeurs des tissus mous (métabolisme), Tumeurs des tissus mous (traitement médicamenteux), Tumeurs des tissus mous (étiologie), Tumeurs du sein (anatomopathologie), Tumeurs du sein (radiothérapie), Tumeurs radio-induites (métabolisme), Tumeurs radio-induites (traitement médicamenteux), Tumeurs radio-induites (étiologie).
- MESH :
- administration et posologie : Mitoxantrone, Paclitaxel.
- anatomopathologie : Carcinome canalaire du sein, Tumeurs du sein.
- métabolisme : Adénosine triphosphate, Lymphangiosarcome, Tumeurs des tissus mous, Tumeurs radio-induites.
- radiothérapie : Carcinome canalaire du sein, Tumeurs du sein.
- traitement médicamenteux : Lymphangiosarcome, Lymphoedème, Tumeurs des tissus mous, Tumeurs radio-induites.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- étiologie : Lymphangiosarcome, Lymphoedème, Tumeurs des tissus mous, Tumeurs radio-induites.
- Femelle, Humains, Perfusions artérielles, Sujet âgé, Syndrome, Tests de criblage d'agents antitumoraux.
English descriptors
- KwdEn :
- Adenosine Triphosphate (metabolism), Aged, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Breast Neoplasms (pathology), Breast Neoplasms (radiotherapy), Carcinoma, Ductal, Breast (pathology), Carcinoma, Ductal, Breast (radiotherapy), Drug Screening Assays, Antitumor, Female, Humans, Infusions, Intra-Arterial, Lymphangiosarcoma (drug therapy), Lymphangiosarcoma (etiology), Lymphangiosarcoma (metabolism), Lymphedema (drug therapy), Lymphedema (etiology), Mitoxantrone (administration & dosage), Neoplasms, Radiation-Induced (drug therapy), Neoplasms, Radiation-Induced (etiology), Neoplasms, Radiation-Induced (metabolism), Paclitaxel (administration & dosage), Soft Tissue Neoplasms (drug therapy), Soft Tissue Neoplasms (etiology), Soft Tissue Neoplasms (metabolism), Syndrome.
- MESH :
- chemical , administration & dosage : Mitoxantrone, Paclitaxel.
- chemical , metabolism : Adenosine Triphosphate.
- drug therapy : Lymphangiosarcoma, Lymphedema, Neoplasms, Radiation-Induced, Soft Tissue Neoplasms.
- etiology : Lymphangiosarcoma, Lymphedema, Neoplasms, Radiation-Induced, Soft Tissue Neoplasms.
- metabolism : Lymphangiosarcoma, Neoplasms, Radiation-Induced, Soft Tissue Neoplasms.
- pathology : Breast Neoplasms, Carcinoma, Ductal, Breast.
- radiotherapy : Breast Neoplasms, Carcinoma, Ductal, Breast.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Aged, Drug Screening Assays, Antitumor, Female, Humans, Infusions, Intra-Arterial, Syndrome.
Abstract
We report on a 72-year-old patient developing Stewart-Treves syndrome (STS) of the right arm 9 years after curative irradiation for ipsilateral stage III breast cancer. Facing the poor track record of both irradiation and chemotherapy in this highly malignant lymphangiosarcoma, amputation was recommended but refused by the patient. Therefore, limb conserving-therapy using three courses of intra-arterial mitoxantrone (MX) and paclitaxel (PTX) was attempted. This novel chemotherapy protocol was selected by pretherapeutic ex vivo ATP-based chemosensitivity testing of autologous tumor tissue. The patient experienced complete response, which was subsequent histologically confirmed by compartment resection. When developing recurrent STS outside of the perfused area 6 months after primary therapy, the patient was retested and reinduced with three other courses of intraarterial MX/PTX which again produced durable complete remission. This case demonstrates the benefit of indivdualized therapy in this prognostically desperate disease allowing both limb conservation and maintained quality of life.
PubMed: 10898542
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004A40
Links to Exploration step
pubmed:10898542Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay.</title><author><name sortKey="Breidenbach, M" sort="Breidenbach, M" uniqKey="Breidenbach M" first="M" last="Breidenbach">M. Breidenbach</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology and Obstetrics, University of Cologne, Germany. Martina.Breidenbach@medizin.uni-koeln.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology and Obstetrics, University of Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Rein, D" sort="Rein, D" uniqKey="Rein D" first="D" last="Rein">D. Rein</name></author><author><name sortKey="Schmidt, T" sort="Schmidt, T" uniqKey="Schmidt T" first="T" last="Schmidt">T. Schmidt</name></author><author><name sortKey="Heindel, W" sort="Heindel, W" uniqKey="Heindel W" first="W" last="Heindel">W. Heindel</name></author><author><name sortKey="Kolhagen, H" sort="Kolhagen, H" uniqKey="Kolhagen H" first="H" last="Kolhagen">H. Kolhagen</name></author><author><name sortKey="Mallmann, P" sort="Mallmann, P" uniqKey="Mallmann P" first="P" last="Mallmann">P. Mallmann</name></author><author><name sortKey="Kurbacher, C M" sort="Kurbacher, C M" uniqKey="Kurbacher C" first="C M" last="Kurbacher">C M Kurbacher</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10898542</idno><idno type="pmid">10898542</idno><idno type="wicri:Area/PubMed/Corpus">004A40</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004A40</idno><idno type="wicri:Area/PubMed/Curation">004A40</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004A40</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay.</title><author><name sortKey="Breidenbach, M" sort="Breidenbach, M" uniqKey="Breidenbach M" first="M" last="Breidenbach">M. Breidenbach</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology and Obstetrics, University of Cologne, Germany. Martina.Breidenbach@medizin.uni-koeln.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology and Obstetrics, University of Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Rein, D" sort="Rein, D" uniqKey="Rein D" first="D" last="Rein">D. Rein</name></author><author><name sortKey="Schmidt, T" sort="Schmidt, T" uniqKey="Schmidt T" first="T" last="Schmidt">T. Schmidt</name></author><author><name sortKey="Heindel, W" sort="Heindel, W" uniqKey="Heindel W" first="W" last="Heindel">W. Heindel</name></author><author><name sortKey="Kolhagen, H" sort="Kolhagen, H" uniqKey="Kolhagen H" first="H" last="Kolhagen">H. Kolhagen</name></author><author><name sortKey="Mallmann, P" sort="Mallmann, P" uniqKey="Mallmann P" first="P" last="Mallmann">P. Mallmann</name></author><author><name sortKey="Kurbacher, C M" sort="Kurbacher, C M" uniqKey="Kurbacher C" first="C M" last="Kurbacher">C M Kurbacher</name></author></analytic><series><title level="j">Anti-cancer drugs</title><idno type="ISSN">0959-4973</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Triphosphate (metabolism)</term><term>Aged</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (radiotherapy)</term><term>Carcinoma, Ductal, Breast (pathology)</term><term>Carcinoma, Ductal, Breast (radiotherapy)</term><term>Drug Screening Assays, Antitumor</term><term>Female</term><term>Humans</term><term>Infusions, Intra-Arterial</term><term>Lymphangiosarcoma (drug therapy)</term><term>Lymphangiosarcoma (etiology)</term><term>Lymphangiosarcoma (metabolism)</term><term>Lymphedema (drug therapy)</term><term>Lymphedema (etiology)</term><term>Mitoxantrone (administration & dosage)</term><term>Neoplasms, Radiation-Induced (drug therapy)</term><term>Neoplasms, Radiation-Induced (etiology)</term><term>Neoplasms, Radiation-Induced (metabolism)</term><term>Paclitaxel (administration & dosage)</term><term>Soft Tissue Neoplasms (drug therapy)</term><term>Soft Tissue Neoplasms (etiology)</term><term>Soft Tissue Neoplasms (metabolism)</term><term>Syndrome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adénosine triphosphate (métabolisme)</term><term>Carcinome canalaire du sein (anatomopathologie)</term><term>Carcinome canalaire du sein (radiothérapie)</term><term>Femelle</term><term>Humains</term><term>Lymphangiosarcome (métabolisme)</term><term>Lymphangiosarcome (traitement médicamenteux)</term><term>Lymphangiosarcome (étiologie)</term><term>Lymphoedème (traitement médicamenteux)</term><term>Lymphoedème (étiologie)</term><term>Mitoxantrone (administration et posologie)</term><term>Paclitaxel (administration et posologie)</term><term>Perfusions artérielles</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Sujet âgé</term><term>Syndrome</term><term>Tests de criblage d'agents antitumoraux</term><term>Tumeurs des tissus mous (métabolisme)</term><term>Tumeurs des tissus mous (traitement médicamenteux)</term><term>Tumeurs des tissus mous (étiologie)</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (radiothérapie)</term><term>Tumeurs radio-induites (métabolisme)</term><term>Tumeurs radio-induites (traitement médicamenteux)</term><term>Tumeurs radio-induites (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Mitoxantrone</term><term>Paclitaxel</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adenosine Triphosphate</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Mitoxantrone</term><term>Paclitaxel</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome canalaire du sein</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphangiosarcoma</term><term>Lymphedema</term><term>Neoplasms, Radiation-Induced</term><term>Soft Tissue Neoplasms</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphangiosarcoma</term><term>Lymphedema</term><term>Neoplasms, Radiation-Induced</term><term>Soft Tissue Neoplasms</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lymphangiosarcoma</term><term>Neoplasms, Radiation-Induced</term><term>Soft Tissue Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Adénosine triphosphate</term><term>Lymphangiosarcome</term><term>Tumeurs des tissus mous</term><term>Tumeurs radio-induites</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Carcinome canalaire du sein</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphangiosarcome</term><term>Lymphoedème</term><term>Tumeurs des tissus mous</term><term>Tumeurs radio-induites</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphangiosarcome</term><term>Lymphoedème</term><term>Tumeurs des tissus mous</term><term>Tumeurs radio-induites</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Screening Assays, Antitumor</term><term>Female</term><term>Humans</term><term>Infusions, Intra-Arterial</term><term>Syndrome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Perfusions artérielles</term><term>Sujet âgé</term><term>Syndrome</term><term>Tests de criblage d'agents antitumoraux</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report on a 72-year-old patient developing Stewart-Treves syndrome (STS) of the right arm 9 years after curative irradiation for ipsilateral stage III breast cancer. Facing the poor track record of both irradiation and chemotherapy in this highly malignant lymphangiosarcoma, amputation was recommended but refused by the patient. Therefore, limb conserving-therapy using three courses of intra-arterial mitoxantrone (MX) and paclitaxel (PTX) was attempted. This novel chemotherapy protocol was selected by pretherapeutic ex vivo ATP-based chemosensitivity testing of autologous tumor tissue. The patient experienced complete response, which was subsequent histologically confirmed by compartment resection. When developing recurrent STS outside of the perfused area 6 months after primary therapy, the patient was retested and reinduced with three other courses of intraarterial MX/PTX which again produced durable complete remission. This case demonstrates the benefit of indivdualized therapy in this prognostically desperate disease allowing both limb conservation and maintained quality of life.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10898542</PMID><DateCreated><Year>2000</Year><Month>10</Month><Day>11</Day></DateCreated><DateCompleted><Year>2000</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0959-4973</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Anti-cancer drugs</Title><ISOAbbreviation>Anticancer Drugs</ISOAbbreviation></Journal><ArticleTitle>Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay.</ArticleTitle><Pagination><MedlinePgn>269-73</MedlinePgn></Pagination><Abstract><AbstractText>We report on a 72-year-old patient developing Stewart-Treves syndrome (STS) of the right arm 9 years after curative irradiation for ipsilateral stage III breast cancer. Facing the poor track record of both irradiation and chemotherapy in this highly malignant lymphangiosarcoma, amputation was recommended but refused by the patient. Therefore, limb conserving-therapy using three courses of intra-arterial mitoxantrone (MX) and paclitaxel (PTX) was attempted. This novel chemotherapy protocol was selected by pretherapeutic ex vivo ATP-based chemosensitivity testing of autologous tumor tissue. The patient experienced complete response, which was subsequent histologically confirmed by compartment resection. When developing recurrent STS outside of the perfused area 6 months after primary therapy, the patient was retested and reinduced with three other courses of intraarterial MX/PTX which again produced durable complete remission. This case demonstrates the benefit of indivdualized therapy in this prognostically desperate disease allowing both limb conservation and maintained quality of life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Breidenbach</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, University of Cologne, Germany. Martina.Breidenbach@medizin.uni-koeln.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rein</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Heindel</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Kolhagen</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mallmann</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kurbacher</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Anticancer Drugs</MedlineTA><NlmUniqueID>9100823</NlmUniqueID><ISSNLinking>0959-4973</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>BZ114NVM5P</RegistryNumber><NameOfSubstance UI="D008942">Mitoxantrone</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007261" MajorTopicYN="N">Infusions, Intra-Arterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008204" MajorTopicYN="N">Lymphangiosarcoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008942" MajorTopicYN="N">Mitoxantrone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009381" MajorTopicYN="N">Neoplasms, Radiation-Induced</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012983" MajorTopicYN="N">Soft Tissue Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10898542</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004A40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:10898542
|texte= Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:10898542" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |